This study describes the use of a novel, two-compartment, static dialysis bag model to study the release, diffusion, and antibacterial activity of a novel, bioresponsive
dextrin-
colistin polymer conjugate against multidrug resistant (MDR) wild-type Acinetobacter baumannii. In this model,
colistin sulfate, at its MIC, produced a rapid and extensive drop in viable bacterial counts (<2 log10 CFU/ml at 4 h); however, a marked recovery was observed thereafter, with regrowth equivalent to that of control by 48 h. In contrast,
dextrin-
colistin conjugate, at its MIC, suppressed bacterial growth for up to 48 h, with 3 log10 CFU/ml lower bacterial counts after 48 h than those of controls. Doubling the concentration of
dextrin-
colistin conjugate (to 2× MIC) led to an initial bacterial killing of 3 log10 CFU/ml at 8 h, with a similar regrowth profile to 1× MIC treatment thereafter. The addition of
colistin sulfate (1× MIC) to
dextrin-
colistin conjugate (1× MIC) resulted in undetectable bacterial counts after 4 h, followed by suppressed bacterial growth (3.5 log10 CFU/ml lower than that of control at 48 h). Incubation of
dextrin-
colistin conjugates with infected
wound exudate from a series of
burn patients (n = 6) revealed an increasing concentration of unmasked
colistin in the outer compartment (OC) over time (up to 86.3% of the initial dose at 48 h), confirming that
colistin would be liberated from the conjugate by endogenous α-
amylase within the
wound environment. These studies confirm the utility of this model system to simulate the pharmacokinetics of
colistin formation in humans administered
dextrin-
colistin conjugates and further supports the development of
antibiotic polymer conjugates in the treatment of MDR
infections.